EPHA2: A Drug Target / Disease Biomarker (G1969)

Target Name: EPHA2

NCBI ID: G1969

EPHA2

EPHA2: A Drug Target / Disease Biomarker

Epha2 (also known as EPH-2) is a protein that is expressed in various tissues of the body, including the skin, hair, and nails. It is a member of the Eph receptor tyrosine kinase family, which is a group of transmembrane proteins that play a crucial role in the development and maintenance of tissues.

One of the main functions of Epha2 is its role in the development and maintenance of the hair. Epha2 is involved in the regulation of cell proliferation and differentiation, as well as in the formation of the extracellular matrix (ECM) that supports hair growth.

In addition to its role in hair development, Epha2 is also involved in the regulation of other tissues and processes in the body. For example, it has been shown to be involved in the development and maintenance of the skin, and is thought to play a role in the regulation of inflammation.

Given its involvement in so many different processes in the body, it is not surprising that Epha2 has become a drug target for various diseases. One of the primary targets for Epha2 is cancer, as it has been shown to be involved in the development and progression of many types of cancer, including skin, lung, and breast cancer.

In addition to its role in cancer, Epha2 has also been shown to be involved in the development and progression of other diseases, including autoimmune disorders and skin diseases.

Overall, Epha2 is a protein that has a wide range of functions in the body, and is an attractive target for drug development for various diseases. Further research is needed to fully understand the role of Epha2 in these processes, and to develop effective treatments for those diseases.

Protein Name: EPH Receptor A2

Functions: Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand-independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis

The "EPHA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPHA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets